title: Should Acetazolamide Be the First-Line Treatment for Patients With Idiopathic Intracranial Hypertension?
authors.affiliation: Department of Neurology and Ophthalmology (DK), Michigan State University, East Lansing, Michigan; and Departments of Neurology and Neurotherapeutics and Ophthalmology (DF), University of Texas Southwestern Medical Center, Dallas, Texas.
authors.forename: David I
authors.initials: DI
authors.lastname: Kaufman
authors.forename: Deborah I
authors.initials: DI
authors.lastname: Friedman
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use*; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D003657:Decision Making; D006801:Humans; D007427:Intracranial Pressure / Q000187:drug effects*; D008279:Magnetic Resonance Imaging; D010211:Papilledema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011559:Pseudotumor Cerebri / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D000086:Acetazolamide